Page 4 - Nabil Abadir News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 Amarin Corporation plc today announced the acceptance of funded research for presentation at the European Society of Cardiology Congress,.

New jerseyUnited statesUnited arab emiratesNoord hollandPascalm burgerGabriel stegColl cardiolHandrean sorenJohnr nelsonMichael millerPeterp tothNabil abadirJannickan dorresteijnDeepakl bhattMark marmurClin cardiol

Amarin Corp (AMRN) Latest Research Evaluating Clinical Benefits of VASCEPA/VAZKEPA to be Presented at ESC Congress

Amarin Corp (AMRN) Latest Research Evaluating Clinical Benefits of VASCEPA/VAZKEPA to be Presented at ESC Congress
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Noord hollandJannickan dorresteijnGabriel stegPeterp tothJohnr nelsonHandrean sorenDeepakl bhattMichael millerPascalm burgerNabil abadirEuropean society of cardiologyAmarin corporationHead of global medical affairsEuropean societyMount sinai heartValentin fuster professor

Amarin Corporation plc: Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events

- New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression - Data Further Advances Understanding of VASCEPA/VAZKEPA Potential Mechanism

United statesLoyola universityNew jerseyUnited arab emiratesMark marmurColl cardiolMarkg rabbatMohamad kassabNabil abadirClin cardiolLisa defrancescoFarouc jafferAmarin pharmaceuticals irelandJournal of the american college cardiologyAmerican heart associationExchange commission

Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events

— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression — Data Further Advances Understanding of VASCEPA/VAZKEPA. | May 12, 2023

United arab emiratesUnited statesNew jerseyLoyola universityClin cardiolNabil abadirFarouc jafferLisa defrancescoMohamad kassabMarkg rabbatMark marmurColl cardiolDrug administrationCorporate communicationsHead of global medical affairsResearch demonstrates multifactorial beneficial

Amarin Corp to Present New Data Evaluating Vascept/Vazkepa (Icosapent Ethyl) at ACC23/WCC

Presentations on Additional REDUCE-IT Sub-Population, In-Vitro Data on EPA to Be Featured at the Congress

United statesFrance generalNabil abadirPreston masonPhillippe gabriel stegSamuelcr sherrattElucida researchHarvard medical schoolHead of global medical affairsAmarin corporationGrade mineral oilCorn oilDepartment of medicineWorld congressNew orleansChief medical officer